ArticleJournal of experimental & clinical cancer research : CR2026
hnRNPA1-SF3B3 interaction drives radioresistance in oral squamous cell carcinoma by modulating MARF1 alternative splicing isoforms.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundRadioresistance remains a major obstacle in oral squamous cell carcinoma (OSCC) therapy. This study aimed to elucidate the role of abnormal alternative splicing (AS) and key splicing factors in this process, focusing on their mechanistic contributions to DNA repair.
methodsWe integrated RNA-sequencing data from irradiated OSCC mouse models with public datasets to profile splicing factor dynamics. Clinical relevance of hnRNPA1 was validated in an OSCC cohort. Functional roles were assessed via clonogenic survival, CCK-8, and xenograft assays. Mechanisms were delineated using co-immunoprecipitation, immunofluorescence, and analysis of MARF1 splicing and downstream DNA repair pathways.
resultshnRNPA1 was significantly upregulated in OSCC tissues and correlated with poor radiotherapy response. Its knockdown suppressed OSCC cell proliferation and impaired DNA double-strand break repair. Mechanistically, hnRNPA1 interacted with SF3B3 to inhibit exon 8 skipping of MARF1, promoting the oncogenic MARF1-L isoform. MARF1-L enhanced radioresistance by degrading PPP1R10, a negative regulator of Chk1, thereby activating homologous recombination repair (HR).
conclusionsThese findings identified hnRNPA1 as a pivotal orchestrator of OSCC radioresistance, which, through an SF3B3-dependent MARF1 splicing switch and subsequent PPP1R10 degradation, activates HR repair. Targeting the hnRNPA1-SF3B3-MARF1 axis presents a novel therapeutic strategy to overcome radioresistance in OSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.